The UK Health Security Agency has announced a change in the vaccine used for the pre-school booster, with REPEVAX® set to replace Boostrix-IPV®. These vaccines are clinically equivalent and should continue to be offered to children aged 3 years 4 months and up to 10 years for those who have not yet received it. However, this change has some operational implications for practices.
Key Changes
From Spring 2025, REPEVAX® will be available for order via ImmForm. Practices should be aware of the following:
•No pre-packed needle: Unlike Boostrix-IPV®, REPEVAX® packs will not include a needle. Practices will need to source needles locally, requiring adjustments to ordering processes and potentially increasing costs.
•Transition Planning: Practices currently using Boostrix-IPV® should plan for a seamless transition to REPEVAX® to avoid disruption in vaccination schedules.
Practical Considerations for Practices
The transition from Boostrix-IPV® to REPEVAX® may seem straightforward, but it introduces a few logistical challenges:
1.Sourcing Needles: Ensure appropriate needles are available through local procurement channels. This step should be factored into ordering and stock management processes.
2.Stock Management: Monitor current supplies of Boostrix-IPV® to minimise waste and ensure that stocks are depleted before transitioning to REPEVAX®.
3.Staff Awareness: Communicate the change to staff, including the absence of pre-packed needles and the new ordering process through ImmForm.
Preparing for the Change
It’s important for practices to:
•Liaise with suppliers to confirm needle availability and ensure consistent supplies ahead of the transition.
•Stay updated on guidance provided on the ImmForm news page for additional details and support.
•Notify teams early about the operational changes and ensure they understand how to handle the new vaccine.
Benefits to Patients and Practices
This change is expected to simplify vaccine supply chains while maintaining clinical effectiveness. For patients, it ensures continued access to the pre-school booster, helping maintain high vaccination coverage. For practices, the key to a smooth transition lies in proactive preparation and clear communication with staff and suppliers.
Ensure your team is ready for this update by Spring 2025, and watch for further information from ImmForm to guide you through the change.